List of Radicava Ors drug patents
Radicava Ors is owned by Mitsubishi Tanabe.
Radicava Ors contains Edaravone.
Radicava Ors has a total of 3 drug patents out of which 0 drug patents have expired.
Radicava Ors was authorised for market use on 12 May, 2022.
Radicava Ors is available in suspension;oral dosage forms.
Radicava Ors can be used as treatment of amyotrophic lateral sclerosis.
The generics of Radicava Ors are possible to be released after 01 November, 2039.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11241416 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(16 years from now) | |
| US10987341 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(16 years from now) | |
| US11478450 | MITSUBISHI TANABE | Edaravone suspension for oral administration |
Nov, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Product (NP) | May 12, 2025 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis
Dosage: SUSPENSION;ORAL
RADICAVA ORS family patents
4
United States
3
Japan
1
Korea, Republic of
1
China
1
Philippines
1
Israel
1
Brazil
1
Taiwan
1
Singapore
1
Argentina
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic